236 related articles for article (PubMed ID: 25326871)
1. Mapping FACT-P to EQ-5D in a large cross-sectional study of metastatic castration-resistant prostate cancer patients.
Diels J; Hamberg P; Ford D; Price PW; Spencer M; Dass RN
Qual Life Res; 2015 Mar; 24(3):591-8. PubMed ID: 25326871
[TBL] [Abstract][Full Text] [Related]
2. Mapping the FACT-P to the preference-based EQ-5D questionnaire in metastatic castration-resistant prostate cancer.
Skaltsa K; Longworth L; Ivanescu C; Phung D; Holmstrom S
Value Health; 2014 Mar; 17(2):238-44. PubMed ID: 24636382
[TBL] [Abstract][Full Text] [Related]
3. Mapping function from FACT-B to EQ-5D-5 L using multiple modelling approaches: data from breast cancer patients in China.
Yang Q; Yu XX; Zhang W; Li H
Health Qual Life Outcomes; 2019 Oct; 17(1):153. PubMed ID: 31615531
[TBL] [Abstract][Full Text] [Related]
4. Comparison of FACT- and EQ-5D-based utility scores in cancer.
Pickard AS; Ray S; Ganguli A; Cella D
Value Health; 2012; 15(2):305-11. PubMed ID: 22433762
[TBL] [Abstract][Full Text] [Related]
5. Mapping CushingQOL scores to EQ-5D utility values using data from the European Registry on Cushing's syndrome (ERCUSYN).
Badia X; Roset M; Valassi E; Franz H; Forsythe A; Webb SM
Qual Life Res; 2013 Dec; 22(10):2941-50. PubMed ID: 23539468
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.
Agarwal N; McQuarrie K; Bjartell A; Chowdhury S; Pereira de Santana Gomes AJ; Chung BH; Özgüroğlu M; Juárez Soto Á; Merseburger AS; Uemura H; Ye D; Given R; Cella D; Basch E; Miladinovic B; Dearden L; Deprince K; Naini V; Lopez-Gitlitz A; Chi KN;
Lancet Oncol; 2019 Nov; 20(11):1518-1530. PubMed ID: 31578173
[TBL] [Abstract][Full Text] [Related]
7. Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients.
Wu EQ; Mulani P; Farrell MH; Sleep D
Value Health; 2007; 10(5):408-14. PubMed ID: 17888106
[TBL] [Abstract][Full Text] [Related]
8. Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial.
Heidenreich A; Chowdhury S; Klotz L; Siemens DR; Villers A; Ivanescu C; Holmstrom S; Baron B; Wang F; Lin P; Shore ND
Eur Urol; 2017 Apr; 71(4):534-542. PubMed ID: 27497762
[TBL] [Abstract][Full Text] [Related]
9. Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease.
Moore A; Young CA; Hughes DA
Value Health; 2018 Nov; 21(11):1322-1329. PubMed ID: 30442280
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study.
Nilsson S; Cislo P; Sartor O; Vogelzang NJ; Coleman RE; O'Sullivan JM; Reuning-Scherer J; Shan M; Zhan L; Parker C
Ann Oncol; 2016 May; 27(5):868-74. PubMed ID: 26912557
[TBL] [Abstract][Full Text] [Related]
11. Health utility and health-related quality of life of Japanese prostate cancer patients according to progression status measured using EQ-5D-5L and FACT-P.
Murasawa H; Sugiyama T; Matsuoka Y; Okabe T; Hino A; Tanaka N; Sugimoto M; Oyama M; Fujimoto K; Horie S; Noto S; Shimozuma K
Qual Life Res; 2019 Sep; 28(9):2383-2391. PubMed ID: 31025290
[TBL] [Abstract][Full Text] [Related]
12. An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA).
Carles J; Pichler A; Korunkova H; Tomova A; Ghosn M; El Karak F; Makdessi J; Koroleva I; Barnes G; Bury D; Özatilgan A; Hitier S; Katolicka J
BJU Int; 2019 Mar; 123(3):456-464. PubMed ID: 30098093
[TBL] [Abstract][Full Text] [Related]
13. Mapping health-related quality of life scores from FACT-G, FAACT, and FACIT-F onto preference-based EQ-5D-5L utilities in non-small cell lung cancer cachexia.
Meregaglia M; Borsoi L; Cairns J; Tarricone R
Eur J Health Econ; 2019 Mar; 20(2):181-193. PubMed ID: 28948436
[TBL] [Abstract][Full Text] [Related]
14. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
Fizazi K; Kramer G; Eymard JC; Sternberg CN; de Bono J; Castellano D; Tombal B; Wülfing C; Liontos M; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Oudard S; Facchini G; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; Bensfia S; de Wit R
Lancet Oncol; 2020 Nov; 21(11):1513-1525. PubMed ID: 32926841
[TBL] [Abstract][Full Text] [Related]
15. Health-Related Quality of Life and Health Utilities in Metastatic Castrate-Resistant Prostate Cancer: A Survey Capturing Experiences from a Diverse Sample of UK Patients.
Lloyd AJ; Kerr C; Penton J; Knerer G
Value Health; 2015 Dec; 18(8):1152-7. PubMed ID: 26686802
[TBL] [Abstract][Full Text] [Related]
16. Health utility scores from EQ-5D and health-related quality of life in patients with esophageal cancer: a real-world cross-sectional study.
Doherty MK; Leung Y; Su J; Naik H; Patel D; Eng L; Kong QQ; Mohsin F; Brown MC; Espin-Garcia O; Vennettilli A; Renouf DJ; Faluyi OO; Knox JJ; MacKay H; Wong R; Howell D; Mittmann N; Darling GE; Cella D; Xu W; Liu G
Dis Esophagus; 2018 Dec; 31(12):. PubMed ID: 29905764
[TBL] [Abstract][Full Text] [Related]
17. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial.
Loriot Y; Miller K; Sternberg CN; Fizazi K; De Bono JS; Chowdhury S; Higano CS; Noonberg S; Holmstrom S; Mansbach H; Perabo FG; Phung D; Ivanescu C; Skaltsa K; Beer TM; Tombal B
Lancet Oncol; 2015 May; 16(5):509-21. PubMed ID: 25888263
[TBL] [Abstract][Full Text] [Related]
18. Development of algorithms to estimate the EQ-5D-5L from the FACT-L in patients with lung cancer: a mapping study.
Jiang L; Zhou H; Yang Q; Luo X; Huang D
Qual Life Res; 2024 Mar; 33(3):805-816. PubMed ID: 38148367
[TBL] [Abstract][Full Text] [Related]
19. EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma: Cross-Sectional Study.
Hernandez G; Garin O; Dima AL; Pont A; Martí Pastor M; Alonso J; Van Ganse E; Laforest L; de Bruin M; Mayoral K; Serra-Sutton V; Ferrer M;
J Med Internet Res; 2019 Jan; 21(1):e10178. PubMed ID: 30672744
[TBL] [Abstract][Full Text] [Related]
20. Mapping the FACT-G to EQ-5D-3L utility index in cancer with the Chinese values set.
He Z; Liang W; Xu W; Huang W; Wang X; Huang K; Yang L
Expert Rev Pharmacoecon Outcomes Res; 2022 Oct; 22(7):1103-1116. PubMed ID: 35711123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
